M
Mario Boccadoro
Researcher at University of Turin
Publications - 670
Citations - 39049
Mario Boccadoro is an academic researcher from University of Turin. The author has contributed to research in topics: Multiple myeloma & Lenalidomide. The author has an hindex of 83, co-authored 638 publications receiving 34589 citations. Previous affiliations of Mario Boccadoro include Mount Sinai Hospital.
Papers
More filters
Journal ArticleDOI
Bortezomib-Doxorubicin-Dexamethasone as Induction Prior to Reduced Intensity Autologous Transplantation Followed by Lenalidomide as Consolidation/Maintenance in Elderly Untreated Myeloma Patients
Antonio Palumbo,Patrizia Falco,Vittorio Montefusco,Claudia Crippa,Francesca Patriarca,Milena Gilestro,Anna Marina Liberati,Fausto Rossini,Tommaso Caravita,Antonietta Falcone,Federica Cavallo,Paolo Corradini,Giuseppe Rossi,Mario Boccadoro +13 more
TL;DR: Bortezomib as induction regimen prior to reduced intensity ASCT, followed by Lenalidomide as consolidation maintenance is a highly effective regimen in elderly patients.
Journal ArticleDOI
Plasma cell dyscrasias: classification, clinical and laboratory characteristics, and differential diagnosis.
TL;DR: It is suggested that plasma cell dyscrasias should be classified simply into two main groups according to the need of immediate chemotherapy, and the appearance of new bone lesions and the increase of the M-component level remain the only two criteria that define malignant transformation.
Journal ArticleDOI
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts
Francesca Patriarca,Maria Teresa Petrucci,Sara Bringhen,Luca Baldini,Tommaso Caravita,Paolo Corradini,Alessandro Corso,Francesco Di Raimondo,Antonietta Falcone,Felicetto Ferrara,Fortunato Morabito,Pellegrino Musto,Massimo Offidani,Mario Petrini,Rita Rizzi,Gianpietro Semenzato,Patrizia Tosi,Angelo Vacca,Michele Cavo,Mario Boccadoro,Antonio Palumbo +20 more
TL;DR: The availability of new targeted therapies has revolutionised the treatment of multiple myeloma, for both the newly diagnosed and the relapsed and refractory settings.
Journal ArticleDOI
Kaposi's sarcoma triggered by endogenous HHV-8 reactivation after non-myeloablative allogeneic haematopoietic transplantation.
Benedetto Bruno,Roberto Sorasio,Patrizia Barozzi,Jeff Vieira,Paola Omedè,Fulvia Giaretta,Marcello Rotta,Luisa Giaccone,Massimo Massaia,Mario Luppi,Mario Boccadoro +10 more
TL;DR: A case in which KS concomitantly occurred with CMV reactivation after a non‐myeloablative allogeneic HCT and presented with skin lesions, but not visceral involvement is described, indicating viral reactivation of the recipient's primary infection.
Journal ArticleDOI
Polyclonal immunoglobulin E levels are correlated with hemoglobin values and overall survival in patients with multiple myeloma.
Giorgia Matta,Silvano Battaglio,Cristiana DiBello,Patrizia Napoli,Cristina Baldi,Giovannino Ciccone,Marta Coscia,Mario Boccadoro,Massimo Massaia +8 more
TL;DR: Because IgE levels are dependent on Th2 responses, these data open new perspectives in the interpretation of antitumor immune responses and pathogenesis of anemia in MM.